Seres Therapeutics Inc
Research Seres Therapeutics Inc (MCRB) on Bullrun: market cap USD 49.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMCRB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 49.14M
- Financial periodQ2 2026
- RevenueUSD 736.00K
- Net incomeUSD 4.58M
- Free cash flow-USD 22.39M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 49.14M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 789.00K | USD 5.70M | USD 865.00K | -729.4% | 0.64 | USD 45.77M | USD 82.97M | USD 44.22M |
| FY2024 | USD 0 | USD 136.00K | -USD 148.99M | n/a | 0 | USD 30.79M | USD 91.64M | USD 13.78M |
| FY2023 | USD 0 | -USD 113.72M | -USD 125.33M | n/a | -17.77 | USD 127.97M | USD 110.00M | -USD 44.86M |
| FY2022 | USD 7.13M | -USD 250.16M | -USD 238.64M | n/a | -2.31 | USD 163.03M | USD 50.00M | USD 10.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 49.14M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 130.27M | 18.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 143.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 180.96M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 697.72M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 765.44M | n/a | n/a | n/a |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Seres Therapeutics Inc's market cap?
Seres Therapeutics Inc's market capitalization is USD 49.14M.
What does Seres Therapeutics Inc do?
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.